Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Altered adrenergic control in hypercholesterolemia.

J Ohanian1, R J Nicolosi, S F Vatner

  • 1Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Journal of Cardiovascular Pharmacology
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Women's responses and understanding of polygenic breast cancer risk information.

Familial cancer·2020
Same author

Use of the ACTH challenge test to identify the predominant glucocorticoid in the southern sea otter (<i>Enhydra lutris nereis</i>).

Conservation physiology·2020
Same author

A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.

Scientific reports·2017
Same author

Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.

The pharmacogenomics journal·2017
Same author

A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis.

CPT: pharmacometrics & systems pharmacology·2016
Same author

Pharmacokinetic indices for cefovecin after single-dose administration to adult sea otters (Enhydra lutris).

Journal of veterinary pharmacology and therapeutics·2016
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

Alpha 1-adrenergic receptor inhibition, used for hypertension, significantly reduced total cholesterol and VLDL+LDL cholesterol in hypercholesterolemic monkeys. This suggests a dual benefit for vascular and lipid health.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Metabolic Research

Background:

  • Hypercholesterolemia and atherosclerosis alter vascular reactivity, with enhanced vasoconstriction via serotonergic mechanisms.
  • Adrenergic mechanisms' role in vascular changes remains unclear, but hypertension therapies like beta-blockers and diuretics can increase serum lipids.
  • Elevated lipids may contribute to vascular abnormalities in hypertensive patients.

Purpose of the Study:

  • To investigate the effects of alpha 1-adrenergic receptor inhibition on plasma lipid levels and vascular reactivity.
  • To examine the potential of prazosin, an alpha 1-adrenergic antagonist, in managing hypercholesterolemia.

Main Methods:

  • Preliminary laboratory study using hypercholesterolemic monkeys.
  • Administration of alpha 1-adrenergic receptor inhibition (prazosin).

Related Experiment Videos

  • Monitoring of plasma cholesterol levels (total, VLDL+LDL) and vascular reactivity.

    • Main Results:

    • Prazosin treatment led to significant reductions in total cholesterol.
    • A notable decrease was observed in the very-low-density lipoprotein (VLDL) + low-density lipoprotein (LDL) cholesterol fraction.
    • Alpha 1-adrenergic receptor inhibition demonstrated a beneficial effect on lipid profiles.

    Conclusions:

    • Alpha 1-adrenergic receptor inhibition, exemplified by prazosin, offers a dual therapeutic advantage.
    • Beyond its antihypertensive effects, it positively impacts lipid metabolism by lowering cholesterol.
    • This suggests a potential role in managing patients with both hypertension and hypercholesterolemia.